Hints and tips:
Related Special Reports
...“Misaligned incentives across the US healthcare system have led to meaningful delays and barriers to biosimilar adoption, resulting in significant missed opportunities for healthcare savings,” the Swiss...
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...Bayer shuns ‘innovation unfriendly’ Europe The German pharmaceutical company has said it is shifting the focus of its drugs business to the US and away from Europe, where governments are making “big mistakes...
...Jefferies analyst Martin Deboo warned that an all-cash deal for £55bn would bring debt to a “prohibitive” 5 times ebitda....
...Even distribution is critical,” said Dr Seth Martin, a cardiologist at Johns Hopkins Hospital....
...Martin Marshall, head of the Royal College of General Practitioners, said: “Right now, the capacity of the service to deliver [vaccinations] is pretty well aligned to the availability of the vaccine . ....
...Martin Marshall, chair of the royal college of GPs, said there was still considerable uncertainty around which vaccines doctors would be allowed to administer, and when....
...over, and poorer countries whose governments are stretched to secure doses for healthcare workers and the most vulnerable....
...Bayer, the German pharmaceutical group, also said it would donate 3m of its malaria tablets, but as they are not approved in the US, they need an emergency authorisation from the FDA....
...The prospect of much lower bond yields — and, crucially, the expectation that central banks will contain any sharp rise — has encouraged investors to boost their exposure to the technology and healthcare...
...The pharmaceutical and healthcare sectors have been among the most active with $479bn worth of transactions announced....
...healthcare”, in which technology is leveraged, on-demand, to create medication specific to the individual....
...The group replaced its chairman in April last year with Martin Barrington, a former chief executive of tobacco group Altria....
...It was this statement of corporate social responsibility — crafted decades before the term became overused PR — which he said had guided the world’s largest healthcare company to become a solid, long-term...
...The pharmaceutical industry is exploring so-called value-based payment as a way to account for high price tags....
...It would top the $120m paid to rival Morgan Stanley when it advised on Monsanto’s $66bn sale to Germany’s Bayer in 2016....
...The 62-year old, who’s a supervisory board member at Bayer, witnessed the unprecedented vote of no confidence that investors delivered to the company last month....
...of the problem, if we start looking at healthcare costs in their totality”....
...At the same time, Gilead said its chairman John Martin would also leave....
...That puts it ahead of its nearest competitors Johnson & Johnson, Sanofi and Bayer, which hold about 4 per cent market shares each....
...Robert Bayer and Ajay Singh have joined Macquarie Capital as senior managing directors in the industrials group. Bayer joins from Guggenheim Securities and Singh from UBS....
...High drug prices are one reason that the US spends more per capita on healthcare than any other developed nation, but has much worse outcomes....
...does much more to push up overall healthcare costs....
...It is not clear if there are bidders left for Pfizer’s consumer healthcare business....
...Reckitt cited financial discipline for quitting the two-horse race, as it also did in 2014, when it withdrew from bidding for the healthcare unit of Merck of the US, leaving Germany’s Bayer to clinch the...
International Edition